Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-11
2007-09-11
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S617000, C546S333000, C546S337000, C564S182000
Reexamination Certificate
active
11145490
ABSTRACT:
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
REFERENCES:
patent: 2809965 (1957-10-01), Wheeler et al.
patent: 5607976 (1997-03-01), Englert et al.
patent: 6204293 (2001-03-01), Sebti et al.
patent: 6727239 (2004-04-01), Chabrier de Lassauniere et al.
patent: 6821992 (2004-11-01), Cooke et al.
patent: 2003/0032623 (2003-02-01), Ban et al.
patent: 2004/0087810 (2004-05-01), Dalton et al.
patent: 2004/0122057 (2004-06-01), Banner et al.
patent: 2004/0229904 (2004-11-01), Bunnage et al.
patent: 2005/0009812 (2005-01-01), Seko et al.
patent: 2005/0014763 (2005-01-01), Brown et al.
patent: 2005/0143317 (2005-06-01), Abdel-Meguid et al.
patent: 2005/0234097 (2005-10-01), Brown et al.
patent: 2005/0282872 (2005-12-01), Hangeland et al.
patent: 1 193 248 (2002-04-01), None
patent: 1-157955 (1989-06-01), None
patent: WO 200039077 (2000-07-01), None
patent: WO 2005/063690 (2005-07-01), None
H. Shinji, “Novel Heterocyclic Derivative and Production Thereof”, Patent Abstracts of Japan, vol. 013, No. 419, 1989.
C. Jamieson et al., “A Rapid Approach for the Optimisation of Polymer Supported Reagents in Synthesis”, Synlett, No. 11, pp. 1603-1607, 2000.
Database Registry, Abstract, XP-002357059, 2004.
Hanney Barbara
Kim Yun-tae
Krout Michael R.
Meissner Robert S.
Mitchell Helen J.
Kosack Joseph R.
Merck & Co. , Inc.
Panzer Curtis C.
Saeed Kamal A.
Shatynski Patricia A.
LandOfFree
N-(2-benzyl)-2-phenylbutanamides as androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(2-benzyl)-2-phenylbutanamides as androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(2-benzyl)-2-phenylbutanamides as androgen receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737902